Eligibility Module
The Eligibility Module contains detailed information about who can participate in the clinical trial. This includes eligibility criteria, age restrictions, gender requirements, healthy volunteer status, and study population descriptions, helping researchers understand who is eligible to participate in the study.
Eligibility Module path is as follows:
Study -> Protocol Section -> Eligibility Module
Eligibility Module
Ignite Creation Date:
2025-12-24 @ 9:34 PM
Ignite Modification Date:
2025-12-24 @ 9:34 PM
NCT ID:
NCT06325332
Eligibility Criteria:
Inclusion Criteria:
* The Kaiser Permanente Northern California, USA (KPNC) member born on or after 01 April 2023 for Cohort 1 and Cohort 2.
* Eligible to receive nirsevimab as defined by the product indication.
* KPNC infants entering their first RSV season.
Exclusion Criteria:
* Mother was administered an RSV vaccine during her pregnancy with the infant participant.
* Mother of infant participant was not a KPNC member during pregnancy.
* Mother did not deliver the infant participant at a KPNC facility.
* Infant receipt of other RSV pre-exposure prophylaxis (ie, Palivizumab).
Note: The above information is not intended to contain all considerations relevant to a potential participation in a clinical trial.
Healthy Volunteers:
True
Sex:
ALL
Minimum Age:
0 Days
Maximum Age:
12 Months
Study:
NCT06325332
Study Brief:
Protocol Section:
NCT06325332